Meeting
2012 ASCO Annual Meeting
Chemotherapy with erlotinib or chemotherapy alone in advanced NSCLC with acquired resistance to EGFR tyrosine kinase inhibitors (TKI).
Authors
Sarah B. Goldberg
Massachusetts General Hospital Cancer Center, Boston, MA
Sarah B. Goldberg , Geoffrey R. Oxnard , Subba Digumarthy , Alona Muzikansky , David Michael Jackman , Inga Tolin Lennes , Lecia V. Sequist
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Lung Cancer - Non-small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Citation
J Clin Oncol 30, 2012 (suppl; abstr 7524)
DOI
10.1200/jco.2012.30.15_suppl.7524
Abstract #
7524
Poster Bd #
14
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
Real-world utilization of EGFR TKI therapies and treatment outcomes in patients with advanced EGFR-sensitizing mutation-positive NSCLC.
First Author: Gregory J. Riely
Poster
2023 ASCO Annual Meeting
Aumolertinib with chemotherapy or alone compared with osimertinib in patients with EGFR-mutant non–small-cell lung cancer (TREBLE).
First Author: Melissa Lynne Johnson
Poster
2021 ASCO Annual Meeting
Activity of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) in patients (pts) with NSCLC with uncommon EGFR mutations: A real-world cohort study (UpSwinG).
First Author: Satoru Miura
Poster
2019 ASCO Annual Meeting
The role of EGFR inhibitors as adjuvant therapy for EGFR mutation positive non-small cell lung cancer.
First Author: Peng Xie